Pfizer/Hospira's Biosimilar Pipeline: Substantial Overlap, Limited Divestiture So Far

All five biosimilars in Pfizer’s clinical pipeline overlap with those in Hospira’s, but even though only infliximab is required to be divested, the others could also be sold off to reach cost-saving targets.